DISPOSITION OF CLOZAPINE AND DESMETHYLCLOZAPINE IN SCHIZOPHRENIC-PATIENTS

被引：34
|
作者：
LIN, SK
CHANG, WH
CHUNG, MC
LAM, YWF
JANN, MW
机构：
[1] TAIPEI CITY PSYCHIAT CTR,BIOL PSYCHIAT LAB,TAIPEI 10510,TAIWAN
[2] UNIV TEXAS,HLTH SCI CTR,DEPT PHARMACOL,DIV CLIN PHARM,SAN ANTONIO,TX 78284
[3] UNIV TEXAS,COLL PHARM,AUSTIN,TX 78712
[4] MERCER UNIV,DEPT PHARM PRACTICE,ATLANTA,GA
[5] MERCER UNIV,DEPT PHARMACEUT SCI,ATLANTA,GA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 1994年 / 34卷 / 04期
关键词：
D O I：
10.1002/j.1552-4604.1994.tb02000.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The disposition of the atypical clozapine and its desmethyl metabolite were evaluated in fourteen male chronic patients. A single 100 mg dose of clozapine was administered and blood sampling performed over the following 72 hours. The mean (SD) oral clearance and half-life of clozapine were 55.4 (29.7) L/hr and 13.7 (9.9) hours, respectively. The mean (SD) AUC for clozapine and desmethylclozapine was 2389.9 (1406) and 751.1 (622.9) ng.hr/mL, respectively. The elimination of the metabolite is rate limited by its formation from cloza-pine. A wide interpatient variability in clozapine and desmethylclozapine pharmacokinetics was observed.
引用
收藏
页码：318 / 324
页数：7
相关论文
共 50 条
  • [31] POLYDIPSIA IN SCHIZOPHRENIC-PATIENTS
    MILLSON, RC
    KOCZAPSKI, AB
    COOK, MI
    JOURNAL OF BEHAVIOR THERAPY AND EXPERIMENTAL PSYCHIATRY, 1989, 20 (01) : 87 - 88
  • [32] PSYCHOIMMUNOLOGY IN SCHIZOPHRENIC-PATIENTS
    RESCH, F
    ASCHAUER, HN
    OPPOLZER, A
    MULLER, C
    ASCHAUERTREIBER, G
    ZIELINSKI, C
    NEUROPSYCHIATRIE, 1992, 6 (1-2): : 17 - 20
  • [33] SCHIZOPHRENIC-PATIENTS AND THEIR SIBLINGS
    LIDZ, T
    ALANEN, YO
    CORNELISON, AR
    FLECK, S
    PSYCHIATRY, 1963, 26 (01): : 1 - &
  • [34] AFTERCARE IN SCHIZOPHRENIC-PATIENTS
    RIEDELL, H
    PSYCHOTHERAPIE PSYCHOSOMATIK MEDIZINISCHE PSYCHOLOGIE, 1980, 30 (01) : 22 - 35
  • [35] SCHIZOPHRENIC-PATIENTS - COMMENTARY
    GUNDERSON, J
    PSYCHIATRY-INTERPERSONAL AND BIOLOGICAL PROCESSES, 1993, 56 (03): : 307 - 309
  • [36] PSYCHOTHERAPY WITH SCHIZOPHRENIC-PATIENTS
    WHITE, RS
    AMERICAN JOURNAL OF PSYCHIATRY, 1989, 146 (10): : 1353 - 1354
  • [37] MALIGNANCIES IN SCHIZOPHRENIC-PATIENTS
    SONI, SD
    GILL, J
    BRITISH JOURNAL OF PSYCHIATRY, 1979, 134 (APR) : 447 - 448
  • [38] RITANSERIN IN SCHIZOPHRENIC-PATIENTS
    VINAR, O
    MOLCAN, J
    NAHUNEK, K
    SVESTKA, J
    ZAPLETALEK, M
    ACTIVITAS NERVOSA SUPERIOR, 1989, 31 (02): : 107 - 109
  • [39] COMMUNICATING WITH SCHIZOPHRENIC-PATIENTS
    ROBINSON, AM
    AMERICAN JOURNAL OF NURSING, 1960, 60 (08) : 1120 - 1123
  • [40] CARBAMAZEPINE IN SCHIZOPHRENIC-PATIENTS
    RIETHLING, AK
    ERNST, K
    MARPERT, M
    NITZSCHE, W
    SCHLAFKE, D
    JOURNAL DE PHARMACOLOGIE, 1986, 17 (02) : 203 - 203
12345